China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 975.53 Million CNY | 35.95% |
| 2022 | 713.57 Million CNY | 33.54% |
| 2021 | 534.36 Million CNY | 26.51% |
| 2020 | 422.39 Million CNY | -11.35% |
| 2019 | 476.48 Million CNY | -3.6% |
| 2018 | 494.29 Million CNY | 21.13% |
| 2017 | 408.06 Million CNY | -27.72% |
| 2016 | 564.59 Million CNY | -8.07% |
| 2015 | 614.18 Million CNY | -12.32% |
| 2014 | 700.52 Million CNY | 1.53% |
| 2013 | 689.97 Million CNY | 2.15% |
| 2012 | 675.44 Million CNY | -28.86% |
| 2011 | 949.5 Million CNY | 0.6% |
| 2010 | 943.83 Million CNY | 12.65% |
| 2009 | 837.87 Million CNY | 88.92% |
| 2008 | 443.51 Million CNY | 20.29% |
| 2007 | 368.7 Million CNY | 8.21% |
| 2006 | 340.73 Million CNY | 5.09% |
| 2005 | 324.24 Million CNY | 15.82% |
| 2004 | 279.95 Million CNY | 51.92% |
| 2003 | 184.27 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | 384.09 Million CNY | 0.0% |
| 2023 Q2 | 586 Million CNY | 0.0% |
| 2023 FY | 970.09 Million CNY | 35.95% |
| 2022 Q4 | 371.64 Million CNY | 0.0% |
| 2022 Q2 | 341.93 Million CNY | 0.0% |
| 2022 FY | 713.57 Million CNY | 33.54% |
| 2021 Q4 | 228.13 Million CNY | 0.0% |
| 2021 FY | 534.36 Million CNY | 26.51% |
| 2021 Q2 | 306.23 Million CNY | 0.0% |
| 2020 FY | 422.39 Million CNY | -11.35% |
| 2020 Q2 | 164.38 Million CNY | 0.0% |
| 2020 Q4 | 258.01 Million CNY | 0.0% |
| 2019 Q2 | 219.76 Million CNY | 0.0% |
| 2019 Q4 | 256.71 Million CNY | 0.0% |
| 2019 FY | 476.48 Million CNY | -3.6% |
| 2018 FY | 494.29 Million CNY | 21.13% |
| 2018 Q4 | 269.84 Million CNY | 0.0% |
| 2018 Q2 | 224.45 Million CNY | 0.0% |
| 2017 Q4 | 229.88 Million CNY | 0.0% |
| 2017 FY | 408.06 Million CNY | -27.72% |
| 2017 Q2 | 178.18 Million CNY | 0.0% |
| 2016 Q2 | 266.86 Million CNY | 0.0% |
| 2016 Q4 | 297.73 Million CNY | 0.0% |
| 2016 FY | 564.59 Million CNY | -8.07% |
| 2015 FY | 614.18 Million CNY | -12.32% |
| 2015 Q2 | 406.77 Million CNY | 0.0% |
| 2015 Q4 | 207.41 Million CNY | 0.0% |
| 2014 Q4 | 293.92 Million CNY | 0.0% |
| 2014 Q2 | 406.59 Million CNY | 0.0% |
| 2014 FY | 700.52 Million CNY | 1.53% |
| 2013 Q4 | 309.8 Million CNY | 0.0% |
| 2013 Q2 | 380.16 Million CNY | 0.0% |
| 2013 FY | 689.97 Million CNY | 2.15% |
| 2012 Q4 | 215.73 Million CNY | 7.9% |
| 2012 Q3 | 199.94 Million CNY | 0.0% |
| 2012 Q2 | 199.94 Million CNY | 0.0% |
| 2012 Q1 | 199.94 Million CNY | 0.0% |
| 2012 FY | 675.44 Million CNY | -28.86% |
| 2011 Q1 | 237.38 Million CNY | 0.0% |
| 2011 Q2 | 237.38 Million CNY | 0.0% |
| 2011 Q3 | 237.38 Million CNY | 0.0% |
| 2011 Q4 | 199.94 Million CNY | -15.77% |
| 2011 FY | 949.5 Million CNY | 0.6% |
| 2010 Q4 | 237.38 Million CNY | -4.26% |
| 2010 Q1 | 247.95 Million CNY | 0.0% |
| 2010 FY | 943.83 Million CNY | 12.65% |
| 2010 Q3 | 247.95 Million CNY | 0.0% |
| 2010 Q2 | 247.95 Million CNY | 0.0% |
| 2009 Q3 | 221 Million CNY | 0.0% |
| 2009 FY | 837.87 Million CNY | 88.92% |
| 2009 Q1 | 221 Million CNY | 0.0% |
| 2009 Q4 | 247.95 Million CNY | 12.19% |
| 2009 Q2 | 221 Million CNY | 0.0% |
| 2008 Q4 | 221 Million CNY | 85.63% |
| 2008 FY | 443.51 Million CNY | 20.29% |
| 2008 Q1 | 119.05 Million CNY | 0.0% |
| 2008 Q2 | 119.05 Million CNY | 0.0% |
| 2008 Q3 | 119.05 Million CNY | 0.0% |
| 2007 Q1 | 143.98 Million CNY | 0.0% |
| 2007 FY | 368.7 Million CNY | 8.21% |
| 2007 Q4 | 119.05 Million CNY | -17.32% |
| 2007 Q3 | 143.98 Million CNY | 0.0% |
| 2007 Q2 | 143.98 Million CNY | 0.0% |
| 2006 Q1 | 96.75 Million CNY | 0.0% |
| 2006 FY | 340.73 Million CNY | 5.09% |
| 2006 Q2 | 96.75 Million CNY | 0.0% |
| 2006 Q3 | 96.75 Million CNY | 0.0% |
| 2006 Q4 | 143.98 Million CNY | 48.81% |
| 2005 Q3 | 85.61 Million CNY | 0.0% |
| 2005 Q2 | 85.61 Million CNY | 0.0% |
| 2005 FY | 324.24 Million CNY | 15.82% |
| 2005 Q4 | 96.75 Million CNY | 13.02% |
| 2005 Q1 | 85.61 Million CNY | 0.0% |
| 2004 Q4 | 85.61 Million CNY | 26.16% |
| 2004 Q1 | 67.86 Million CNY | 0.0% |
| 2004 Q2 | 67.86 Million CNY | 0.0% |
| 2004 Q3 | 67.86 Million CNY | 0.0% |
| 2004 FY | 279.95 Million CNY | 51.92% |
| 2003 FY | 184.27 Million CNY | 0.0% |
| 2003 Q1 | 36.01 Million CNY | 0.0% |
| 2003 Q4 | 67.86 Million CNY | 88.43% |
| 2003 Q3 | 36.01 Million CNY | 0.0% |
| 2003 Q2 | 36.01 Million CNY | 0.0% |
| 2002 Q4 | 36.01 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -582.135% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 63.373% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 12052.156% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -2286.338% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 1969.45% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -2606.662% |
| Essex Bio-Technology Limited | 310.32 Million HKD | -214.354% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 1577.054% |
| SSY Group Limited | 1.63 Billion HKD | 40.476% |
| JBM (Healthcare) Limited | 174.2 Million HKD | -459.993% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | -192.843% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 91.969% |